JP2022547552A5 - - Google Patents
Info
- Publication number
- JP2022547552A5 JP2022547552A5 JP2022515826A JP2022515826A JP2022547552A5 JP 2022547552 A5 JP2022547552 A5 JP 2022547552A5 JP 2022515826 A JP2022515826 A JP 2022515826A JP 2022515826 A JP2022515826 A JP 2022515826A JP 2022547552 A5 JP2022547552 A5 JP 2022547552A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898896P | 2019-09-11 | 2019-09-11 | |
| US62/898,896 | 2019-09-11 | ||
| US202062985808P | 2020-03-05 | 2020-03-05 | |
| US62/985,808 | 2020-03-05 | ||
| PCT/US2020/050090 WO2021050656A1 (en) | 2019-09-11 | 2020-09-10 | Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547552A JP2022547552A (ja) | 2022-11-14 |
| JP2022547552A5 true JP2022547552A5 (enExample) | 2023-09-14 |
| JP7682859B2 JP7682859B2 (ja) | 2025-05-26 |
Family
ID=74849499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515826A Active JP7682859B2 (ja) | 2019-09-11 | 2020-09-10 | 前立腺幹細胞抗原（ｐｓｃａ）キメラ抗原受容体（ｃａｒ）を含む組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11766453B2 (enExample) |
| EP (1) | EP4028414A4 (enExample) |
| JP (1) | JP7682859B2 (enExample) |
| CN (1) | CN114729059A (enExample) |
| AU (1) | AU2020347171A1 (enExample) |
| WO (1) | WO2021050656A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230203125A1 (en) * | 2020-05-22 | 2023-06-29 | Chongqing Precision Biotech Co., Ltd. | Fusion protein for reversing tumor microenvironment and use thereof |
| CN118922196A (zh) * | 2022-02-18 | 2024-11-08 | 加利福尼亚大学董事会 | 嵌合细胞因子受体促进原代人nk细胞扩增和功能 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008529556A (ja) | 2005-02-18 | 2008-08-07 | メダレックス， インク． | 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 |
| WO2009032949A2 (en) * | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| EP2370467B1 (en) | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| JP6493692B2 (ja) | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたｔリンパ球 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CA2964958A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified t cells |
| EP3359574B1 (en) * | 2015-10-06 | 2020-04-22 | City of Hope | Chimeric antigen receptors targeted to psca |
| EP3464379B1 (en) | 2016-06-06 | 2023-09-27 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| CN108395480A (zh) * | 2017-02-08 | 2018-08-14 | 广州百尼夫生物科技有限公司 | 嵌合抗原受体及其基因和重组表达载体、carher2-nkt细胞及其制备方法和应用 |
| KR20190133017A (ko) * | 2017-03-27 | 2019-11-29 | 에프. 호프만-라 로슈 아게 | 개선된 항원 결합 수용체 구성 |
| WO2018191490A1 (en) | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| CN109593726A (zh) | 2018-12-26 | 2019-04-09 | 重庆精准生物技术有限公司 | 增强car-t细胞归巢到实体肿瘤组织能力的试剂及其应用 |
-
2020
- 2020-09-10 CN CN202080078234.1A patent/CN114729059A/zh active Pending
- 2020-09-10 US US17/017,238 patent/US11766453B2/en active Active
- 2020-09-10 EP EP20863540.9A patent/EP4028414A4/en active Pending
- 2020-09-10 AU AU2020347171A patent/AU2020347171A1/en active Pending
- 2020-09-10 WO PCT/US2020/050090 patent/WO2021050656A1/en not_active Ceased
- 2020-09-10 JP JP2022515826A patent/JP7682859B2/ja active Active
-
2023
- 2023-09-08 US US18/463,630 patent/US20240041921A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547552A5 (enExample) | ||
| CN107847574B (zh) | Pd-1结合分子和其使用方法 | |
| KR102629403B1 (ko) | Vista 항원 결합 분자 | |
| JP7796079B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| JP2022548778A5 (enExample) | ||
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP6378087B2 (ja) | Ｂｃｍａおよびｃｄ３に対する結合分子 | |
| KR20200079511A (ko) | Cd47 항원-결합 분자 | |
| JP2018503401A5 (enExample) | ||
| KR20110066960A (ko) | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 | |
| JP2022542559A5 (enExample) | ||
| AU2020267504A1 (en) | Materials and methods for modulating T cell mediated immunity | |
| IL298449A (en) | Improved antigen binding receptors | |
| AU2018315432A1 (en) | CD96-binding agents as immunomodulators | |
| WO2022056197A9 (en) | Immune targeting molecules and uses thereof | |
| CA3175134A1 (en) | Materials and methods for modulating delta chain mediated immunity | |
| CA3227854A1 (en) | Novel anti-sirpa antibodies | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| JP2025504795A (ja) | 抗体及びその用途 | |
| CN117355540A (zh) | 抗cd137抗体和使用方法 | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| EP4326774A1 (en) | Kidney-glomerular targeted immunotherapy | |
| WO2025103456A1 (en) | Gprc5d-binding moieties, chimeric antigen receptors and uses thereof | |
| US20250270318A1 (en) | Multispecific antibodies and uses thereof | |
| RU2805648C2 (ru) | Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения |